Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. - Wikidata - wikimedia - TriplyDB

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

http://www.wikidata.org/entity/Q34545931

about

Adding pharmacogenomics to the development of new marine-derived anticancer agents Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives The value of trabectedin in the treatment of soft tissue sarcoma Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review Trabectedin for advanced soft tissue sarcomas: optimizing use Major clinical research advances in gynecologic cancer in 2015 Trabectedin in soft tissue sarcomas Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin Pazopanib in the treatment of soft tissue sarcoma Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells The evolution of systemic therapy in sarcoma.Trabectedin and its potential in the treatment of soft tissue sarcoma.Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.Trabectedin for the management of soft-tissue sarcoma.Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma.Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group.Cost-effectiveness of pazopanib in advanced soft tissue sarcoma in the United kingdom.Role of trabectedin in the treatment of soft tissue sarcoma Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program.Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma.Trabectedin: safety and efficacy in the treatment of advanced sarcoma Case Report of Suspected Rhabdomyolysis during Treatment with Trabectedin in a Patient with Metastatic Leiomyosarcoma Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.Recent advances in understanding and managing leiomyosarcomas Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients Intracranial meningeal hemangiopericytoma: Recurrences at the initial and distant intracranial sites and extraneural metastases to multiple organs.Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study.Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin.Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches New drug developments for patients with metastatic soft tissue sarcoma.A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors

P2860

Q25254985-49A9F726-6261-4138-995E-2D856A3DABD6 Q26738346-5155D0C5-9F13-4537-8242-7A41C3A83800 Q26745502-E57914C5-647A-42D8-B1BB-F5638F9EE35C Q26772855-8326517D-C852-4162-A446-B7DDD29A5CBC Q26822530-4009F04C-181C-4E8A-B4CE-FD3335C07FA1 Q26860365-BF541903-B807-4F2C-8334-ED64DC06E234 Q28077183-F17E4AB1-DE0E-4E18-A1E6-A317A9D55B96 Q28085505-03E347CB-9A02-450F-9A9C-D70BC23CD7B5 Q28087771-34303E70-3F01-451C-88A4-7CB6F6E8EA46 Q28269229-3D47BACC-59D8-4393-AB68-02CB1B5B0A61 Q28307320-C5A3A641-5EE0-4AC8-A551-66EB7C304C8C Q33274710-C51AB608-D52F-402A-84B5-EDA4AF54ADC0 Q33380903-0AA5693D-B139-45B9-8BDE-4E3FC4D1C5D6 Q33381641-EE0E30A1-093B-4C9D-8C58-6CDC3908EE7A Q33384836-091CB9D6-E537-470E-A834-8B155B25B825 Q33392364-2327B5CB-2CA7-4638-AFE5-B60D685FC44D Q33400959-61A31FD6-A246-4E53-A704-B0C94DF86EDD Q33426789-14FAE62D-E5EB-44EF-9EA6-CE203E95A2FA Q33850011-F820CF63-80BB-412B-8089-60357DAD2A33 Q33916011-0D842CF6-21D0-4E55-B5B7-AF7CEFAA6564 Q34356540-171C5CF9-5D87-4482-82C4-33DAA22BC64D Q34578850-838F8FEE-8B18-4D13-A2D7-C5A9A1B3E243 Q34580659-D3699FCA-557E-44D4-B15B-804278AD0B0D Q34581388-7F937F7D-FE08-4F4B-BAF8-3DF8780E5968 Q34622323-1E4ED915-3787-49DB-A131-B344B95A8743 Q34628607-2B6EBA4A-447A-4567-8138-F91F0A302D4D Q34629491-D3ABA53D-7647-4071-B8F6-4416ED0845E5 Q34647970-F5C6192E-6516-4C54-B0ED-0F8123F55525 Q34670825-BF2343C6-5C19-4DDE-997F-8E9731EB3814 Q34736667-9314BF45-544A-42FB-B0C3-DD24F89A5B63 Q35098302-7946399D-9694-47C7-985C-3408E58DACD0 Q35246995-8F3A08CF-9339-41A8-BC7A-5B5E8AA658F3 Q35676502-75260FC2-B10F-4ACB-9FBE-EABB93925899 Q35803588-E8DF5CBC-52C9-4B7B-9706-197ABAE22D5B Q35898258-36B5FF34-D10A-4BA9-B4C3-C9D97CC1DCEA Q35909766-05BF2D80-B80E-44A0-9D25-F5A2CDCF6148 Q35996144-D8AC96AC-73C7-4029-AE96-97CBB30752F9 Q36144210-DA6C86C7-E79D-455E-BA96-ABF469FC7531 Q36157324-39928F79-D89E-41CF-AD61-93D5FF431B5E Q36233516-FF1A4A2F-6271-4FE0-821E-4192B7336DCD

P2860

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

http://www.wikidata.org/entity/Q34545931

description

2004 nî lūn-bûn

@nan

2004 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի մարտին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

@ast

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

@en

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

@nl

type

label

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

@ast

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

@en

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

@nl

prefLabel

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

@ast

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

@en

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

@nl

P1433

Q34545931-5D45EE0D-E244-4D4E-B643-1CC09764ADB5

P1476

Q34545931-4D9E210B-2891-4845-874D-64B8B84EFB8A

P2093

Q34545931-126A63BE-457C-4A71-A5B5-92ADCB79E7F9

Q34545931-1398AE8D-109A-4AF3-BAC1-B0102699CC45

Q34545931-20A08F15-8A48-47F0-9D08-10EE298F05E8

Q34545931-2B612F6B-0CF3-4E76-A453-66CEAB13BB21

Q34545931-4D9C7CA0-1F7D-4861-B1F3-881C4215C61A

Q34545931-52B85AE0-1ACE-4FF1-962F-14A833DB3BEE

Q34545931-57DDE863-BDE5-447D-A81F-778FDD97E036

Q34545931-A3C81075-5574-4C27-B78E-640B1E9BC815

Q34545931-B9BDE543-4EC8-4BBA-95A1-A30B4464D65A

Q34545931-D4AEDE16-6827-4464-865D-6E0DC030F0CF

P304

Q34545931-E8E2D2B0-44A2-4AB6-8BCC-E87CECCE18C8

P31

Q34545931-94A2705A-9935-4C80-8930-EA3D3AFE0238

P356

Q34545931-0EFBB459-20CB-4B0E-9088-2276EC7324C0

P407

Q34545931-AEDB6891-DD48-417F-B777-F23386D51EB7

P433

Q34545931-5404B5E4-2EA6-4183-9D6C-29D7507907C0

P478

Q34545931-7D04730E-5C64-48B4-8D78-0B42859434AB

P50

Q34545931-A151A7FD-7895-4A1D-AF53-AA1DA0AAA429

P577

Q34545931-1B247494-65FB-4F79-B8E4-7912DEBB6218

P698

Q34545931-03277887-73EB-4A06-BA32-F0FE46648061

P356

JCO.2004.05.210

P1433

Journal of Clinical Oncology

P1476

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

@en

P2093

A Taamma

http://www.w3.org/2001/XMLSchema#string

A Yovine

http://www.w3.org/2001/XMLSchema#string

C Kahatt

http://www.w3.org/2001/XMLSchema#string

C Martin

http://www.w3.org/2001/XMLSchema#string

E Brain

http://www.w3.org/2001/XMLSchema#string

E Cvitkovic

http://www.w3.org/2001/XMLSchema#string

J Alexandre

http://www.w3.org/2001/XMLSchema#string

J Jimeno

http://www.w3.org/2001/XMLSchema#string

J L Misset

http://www.w3.org/2001/XMLSchema#string

M Riofrio

http://www.w3.org/2001/XMLSchema#string

P304

890-899

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2004.05.210

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14990645

http://www.w3.org/2001/XMLSchema#string